Supply chain report: make CMO agreements public, but ‘glib’ onshoring not the answer
A new report commissioned by the US Congress recommends that the FDA should make drug supply chain information public.
By
Pharma
Latest in
Pharma
Bluebird bio’s gene therapy Zynteglo could have high price tag defense in beta thalassemia
A $1 million price point is not out of question for bluebird bio’s beta thalassemia therapy if long-term benefits are…
By
An uphill battle for insulin pricing reform as copay cap bill enters US Senate
Congress has renewed its longstanding push for insulin pricing reform with the Affordable Insulin Now Act, but will it be…
By
Insulin pricing: could an e-commerce approach cut costs?
An e-commerce drug delivery approach could put a dent in upward spiraling insulin prices, but uptake challenges loom large.
By
Navigating distribution challenges for rare disease drugs
On Rare Disease Day, Pharmaceutical Technology explores how specialty pharmacies and value-based contracts could shape drug distribution.
By
Cutting the carbon footprint of pharma’s supply chain
The pharma industry needs to target its entire value chain if it wants to make a real dent in reducing…
By
Macro view: Omicron outbreak forces lockdown in New South Wales
Some economists state that the Omicron outbreak has sparked a de facto lockdown in New South Wales, forcing businesses to…
ESG in clinicals trials: What pharma needs to know
AI is main investment target, while 3D printing remains a largely untapped area.
By